ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $228,671,218 | -9.1% | 8,425,616 | +2.9% | 0.01% | 0.0% |
Q2 2023 | $251,663,400 | -16.3% | 8,186,838 | -1.8% | 0.01% | -23.5% |
Q1 2023 | $300,519,204 | -53.2% | 8,340,805 | -48.6% | 0.02% | -10.5% |
Q4 2022 | $641,795,474 | +101.6% | 16,239,764 | +105.0% | 0.02% | -5.0% |
Q3 2022 | $318,282,000 | -1.0% | 7,921,415 | +3.6% | 0.02% | +5.3% |
Q2 2022 | $321,385,000 | +6.3% | 7,644,740 | -1.5% | 0.02% | +26.7% |
Q1 2022 | $302,430,000 | +7.2% | 7,762,572 | +9.7% | 0.02% | +15.4% |
Q4 2021 | $282,032,000 | +33.7% | 7,077,330 | +21.3% | 0.01% | +18.2% |
Q3 2021 | $210,868,000 | +5.7% | 5,834,745 | +19.9% | 0.01% | 0.0% |
Q2 2021 | $199,524,000 | -2.4% | 4,867,634 | +3.9% | 0.01% | -8.3% |
Q1 2021 | $204,397,000 | +73.2% | 4,685,863 | +98.7% | 0.01% | +71.4% |
Q4 2020 | $118,005,000 | +175.5% | 2,357,742 | +131.6% | 0.01% | +133.3% |
Q3 2020 | $42,835,000 | +2062.3% | 1,018,194 | +2395.6% | 0.00% | – |
Q2 2020 | $1,981,000 | – | 40,800 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
Brown University | 381,759 | $16,652,000 | 11.44% |
Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |